The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples